<code id='7826D661B5'></code><style id='7826D661B5'></style>
    • <acronym id='7826D661B5'></acronym>
      <center id='7826D661B5'><center id='7826D661B5'><tfoot id='7826D661B5'></tfoot></center><abbr id='7826D661B5'><dir id='7826D661B5'><tfoot id='7826D661B5'></tfoot><noframes id='7826D661B5'>

    • <optgroup id='7826D661B5'><strike id='7826D661B5'><sup id='7826D661B5'></sup></strike><code id='7826D661B5'></code></optgroup>
        1. <b id='7826D661B5'><label id='7826D661B5'><select id='7826D661B5'><dt id='7826D661B5'><span id='7826D661B5'></span></dt></select></label></b><u id='7826D661B5'></u>
          <i id='7826D661B5'><strike id='7826D661B5'><tt id='7826D661B5'><pre id='7826D661B5'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:hotspot    Page View:55881
          George Yancopoulos on the 2024 Breakthrough Summit East stage.
          George Yancopoulos on the 2024 Breakthrough Summit East stage STAT

          George Yancopoulos is in touch with his teenage self.

          After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has led the development of 12 approved medicines, turning a once-fledgling company into the $100 billion global drugmaker it is today. And you can trace a straight line back to the childhood fascination with science he fostered growing up in Woodside, Queens.

          advertisement

          “My high school science project was about regenerating neurons, and ‘Regeneron’ is a contraction of ‘regenerating neurons,’” Yancopoulos said at the STAT Summit East on Thursday. “In some ways I’m still working on my high school science project.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial
          Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCJapanesedrugmakerNipponShinyakusaidon

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Should insurance cover cosmetic surgery?

          ATTAKENARE/AFP/GettyImagesShouldinsurancecoverbreastaugmentation,theprocedurecommonlyknownasaboobjob